News | April 28, 2014

Cardiosonic Received CE Mark for TIVUS Ablative Catheter Device

Cardiosonic Inc CE mark TIVUS ablative catheter renal denervation hypertension

April 28, 2014 — Cardiosonic Ltd. announced CE marking of its TIVUS (therapeutic intravascular ultrasound) ablative catheter device.

The core of the company's technology is a miniaturized ultrasonic transducer, located at the tip of a flexible catheter and capable of emitting ultrasonic waves, which creates controllable levels of heat for selective tissue ablation.

The first application of the TIVUS catheter is renal denervation (RDN) for the treatment of resistant hypertension.

Animal testing has shown that the TIVUS non-focused ultrasonic energy penetrates the artery wall and causes nerve ablation at a depth range of 0.5 mm to 10 mm, enabling a more complete nerve ablation than radio frequency energy, which damages the vessel wall and penetrates half as deep as TIVUS.

The TIVUS system has been evaluated in two multi-center clinical trials in Europe, Australia and Israel. The TIVUS II trial enrolled 25 patients and has shown an average reduction in blood pressure versus baseline of 38 mmHg. Benny Dilmoney, the company's CEO, commented: "The impressive drop in blood pressure is due to a high level of renal nerves ablation, made possible by the fact that ultrasonic heat waves penetrate much deeper into the artery tissues than any other ablation methods in use, mainly RF."

Cardiosonic now intends to carry out the TIVUS III study, which will further assess the TIVUS technology in a controlled manner. Dilmoney expressed confidence that the results obtained in the TIVUS II study will be replicated in the planned follow-up TIVUS III study.

Other applications of the company's technology include the treatment of pulmonary hypertension, COPD, asthma and atrial fibrillation (AF). The company has completed encouraging preliminary animal work in all of these areas.

For more information:

Related Content

Most Black Adults Have High Blood Pressure Before Age 55
News | Hypertension | July 30, 2018
July 30, 2018 — Approximately 75 percent of black and men women are...
American Heart Association Announces New Hypertension Center Certification
News | Hypertension | July 05, 2018
Physician practices now have access to new resources to improve their standard of quality care for hypertension...
YMCA and American Heart Association Partner to Improve Blood Pressure Control
News | Hypertension | April 05, 2018
YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better...
Higi Implementing New ACC/AHA Blood Pressure Guidelines at 11,000 North American Stations
News | Hypertension | March 28, 2018
Population health enablement company Higi announced their commitment to implement the 2017 American College of...
Petaluma Health Center Wins 2017 HIMSS Davies Award for Hypertension Control Program
News | Hypertension | February 16, 2018
February 16, 2018 — California’s Petaluma Health Center (PHC) was recently awarded a 2017 Healthcare Information and
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension | November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension | September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension | September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension | August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension | August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init